Last Updated: May 10, 2026

Suppliers and packagers for trilyte


✉ Email this page to a colleague

« Back to Dashboard


trilyte

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Aurobindo Pharma Usa TRILYTE polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride FOR SOLUTION;ORAL 076491 ANDA Aurobindo Pharma Limited 84386-013-04 4 L in 1 BOTTLE (84386-013-04) 2026-04-14
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Trilyte: What suppliers provide the drug’s key materials and finished product?

Last updated: May 2, 2026

What is “Trilyte” in the supply chain context?

“Trilyte” is a branded bowel preparation product (prescription laxative) used for colon cleansing prior to colonoscopy and related procedures. In practice, “suppliers” for Trilyte fall into two buckets:

  1. Finished-goods manufacturers that produce and label Trilyte dosage forms under the brand owner’s authorizations.
  2. Component and packaging suppliers that provide excipients, active and inactive ingredients, and container-closure systems used to make the finished product.

Which suppliers are tied to Trilyte’s finished product?

Public, product-specific supplier identification for branded pharmaceuticals is highly constrained because registrations, manufacturer identities, and contract manufacturing arrangements are not always disclosed in publicly searchable marketing materials. Without verified, source-backed manufacturer and labeler details for “Trilyte” in the jurisdiction of interest, supplier lists cannot be produced accurately.

What suppliers provide the major input categories for bowel-prep formulations like Trilyte?

For bowel-prep products in this class, the typical supply chain inputs that are bought from industrial suppliers include:

  • Active ingredient(s / osmotic agents (the formulation-defining components used for bowel cleansing)
  • Major excipients (electrolytes, acids/bases for pH control, flavorants, and dissolution aids)
  • Packaging
    • primary packaging (bottles/sachets depending on the specific presentation)
    • closures (child-resistant or standard caps)
    • secondary packaging (cartons, labels, leaflets)

These are supplied by specialty chemical manufacturers and packaging manufacturers operating under GMP with qualification packages for pharmaceutical use. However, naming specific vendors for “Trilyte” requires product-verified sourcing documents (labeler, manufacturer, and NDA/ANDA-related manufacturing sites) that are not provided here.

Which regulatory artifacts normally identify Trilyte suppliers?

Supplier identities are typically established through these sources:

  • FDA Orange Book entries (manufacturer and applicant/labeler linkage for specific NDCs)
  • FDA drug establishment registration and listing (DERL) for the registered manufacturing sites for the specific marketed NDC
  • NDC directory and labeler-of-record pages (labeler and sometimes manufacturing site mapping)
  • US Prescribing Information / package insert “Manufactured for” or “Distributed by” sections that name the responsible party

Without the specific Trilyte presentation and the jurisdiction/NDC mapping, supplier names cannot be grounded to a verifiable record.

Key constraints: “Trilyte” naming and presentation drives supplier identification

“Trilyte” can be marketed in multiple presentations (for example, powder vs liquid systems; unit-dose vs bottle formats) and across markets that use different NDCs and labelers. Supplier identification must match:

  • exact NDC (or local equivalent)
  • exact strength/presentation
  • exact labeler/manufacturer at that time

A supplier list that mixes presentations or mixes NDCs can produce incorrect “suppliers,” especially where multiple contract manufacturing sites exist.


Key Takeaways

  • “Suppliers for Trilyte” resolve into finished-goods manufacturers and input/package suppliers.
  • Accurate supplier naming requires product-verified identifiers (NDC/labeler/manufacturer site), which are not provided here.
  • Without a source-backed mapping to the exact marketed product identifiers, producing a supplier list would be guesswork.

FAQs

  1. What counts as a “supplier” for Trilyte?
    The supplier is either the finished-goods manufacturer/labeler of record or the qualified suppliers providing key ingredients and packaging under GMP.

  2. Can I use ingredient suppliers to infer the Trilyte finished-goods supplier?
    No. Input ingredient suppliers often provide many brands; the finished-goods supplier is tied to the specific NDC and manufacturing site.

  3. Where do accurate Trilyte supplier names usually come from?
    FDA Orange Book, drug establishment registration/listing, and the package insert “manufactured for” statements.

  4. Why do Trilyte supplier lists change over time?
    Manufacturing sites and contract manufacturing relationships can change while the brand stays constant, so the supplier list must match the current NDC and labeler.

  5. Does Trilyte have different suppliers by presentation?
    Yes. Different presentations and strengths map to different NDCs, which can map to different manufacturers and packaging systems.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.